Plasma Pro-B-Type Natriuretic Peptide Testing as a Screening Method for Hypertrophic Cardiomyopathy

dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFERNANDES, Fabio
dc.contributor.authorARTEAGA-FERNANDEZ, Edmundo
dc.contributor.authorANTUNES, Murillo de Oliveira
dc.contributor.authorBUCK, Paula
dc.contributor.authorMARSIGLIA, Julia Daher Carneiro
dc.contributor.authorMATSUMOTO, Afonso
dc.contributor.authorNASTARI, Luciano
dc.contributor.authorKRIEGER, Jose Eduardo
dc.contributor.authorPEREIRA, Alexandre Costa
dc.contributor.authorMADY, Charles
dc.date.accessioned2013-10-02T19:19:12Z
dc.date.available2013-10-02T19:19:12Z
dc.date.issued2012
dc.description.abstractBackground: Clinical multistage risk assessment associated with electrocardiogram (ECG) and NT-proBNP may be a feasible strategy to screen hypertrophic cardiomyopathy (HCM). We investigated the effectiveness of a screening based on ECG and NT-proBNP in first-degree relatives of patients with HCM. Methods and Results: A total of 106 first-degree relatives were included. All individuals were evaluated by echocardiography, ECG, NT-proBNP, and molecular screening (available for 65 individuals). From the 106 individuals, 36 (34%) had diagnosis confirmed by echocardiography. Using echocardiography as the gold standard, ECG criteria had a sensitivity of 0.71, 0.42, and 0.52 for the Romhilt-Estes, Sokolow-Lyon, and Cornell criteria, respectively. Mean values of NT-ProBNP were higher in affected as compared with nonaffected relatives (26.1 vs. 1290.5, P < .001). The AUC of NT-proBNP was 0.98. Using a cutoff value of 70 pg/mL, we observed a sensitivity of 0.92 and specificity of 0.96. Using molecular genetics as the gold standard, ECG criteria had a sensitivity of 0.67, 0.37, and 0.42 for the Romhilt-Estes, Sokolow-Lyon, and Cornell criteria, respectively. Using a cutoff value of 70 pg/mL, we observed a sensitivity of 0.83 and specificity of 0.98. Conclusion: Values of NT-proBNP above 70 pg/mL can be used to effectively select high-risk first-degree relatives for HCM screening. (J Cardiac Fail 2012;18:564-568)
dc.description.indexMEDLINE
dc.identifier.citationJOURNAL OF CARDIAC FAILURE, v.18, n.7, p.564-568, 2012
dc.identifier.doi10.1016/j.cardfail.2012.04.005
dc.identifier.issn1071-9164
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/2502
dc.language.isoeng
dc.publisherCHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
dc.relation.ispartofJournal of Cardiac Failure
dc.rightsrestrictedAccess
dc.rights.holderCopyright CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
dc.subjectHypertrophic cardiomyopathy
dc.subjectNT-proBNP
dc.subjectfamilial screening
dc.subject.otherleft-ventricular hypertrophy
dc.subject.otherdiastolic dysfunction
dc.subject.otherin-vitro
dc.subject.othergenotype
dc.subject.otherpoint
dc.subject.otherage
dc.subject.wosCardiac & Cardiovascular Systems
dc.titlePlasma Pro-B-Type Natriuretic Peptide Testing as a Screening Method for Hypertrophic Cardiomyopathy
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus6
hcfmusp.contributor.author-fmusphcFERNANDES, Fabio
hcfmusp.contributor.author-fmusphcARTEAGA-FERNANDEZ, Edmundo
hcfmusp.contributor.author-fmusphcANTUNES, Murillo de Oliveira
hcfmusp.contributor.author-fmusphcBUCK, Paula
hcfmusp.contributor.author-fmusphcMARSIGLIA, Julia Daher Carneiro
hcfmusp.contributor.author-fmusphcMATSUMOTO, Afonso
hcfmusp.contributor.author-fmusphcNASTARI, Luciano
hcfmusp.contributor.author-fmusphcKRIEGER, Jose Eduardo
hcfmusp.contributor.author-fmusphcPEREIRA, Alexandre Costa
hcfmusp.contributor.author-fmusphcMADY, Charles
hcfmusp.description.beginpage564
hcfmusp.description.endpage568
hcfmusp.description.issue7
hcfmusp.description.volume18
hcfmusp.jcrJ CARD FAIL
hcfmusp.lim.ref2012
hcfmusp.origemWOS
hcfmusp.origem.pubmed22748490
hcfmusp.origem.scopus2-s2.0-84863008691
hcfmusp.origem.wosWOS:000306386700007
hcfmusp.publisher.cityPHILADELPHIA
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAla-Kopsala M, 2010, CLIN CHEM, V56, P1822, DOI 10.1373/clinchem.2010.148775
hcfmusp.relation.referenceArteaga E, 2005, AM HEART J, V149, P1099, DOI 10.1016/j.ahj.2004.09.049
hcfmusp.relation.referenceArteaga E, 2005, AM HEART J, V150, P1228, DOI 10.1016/j.ahj.2005.02.045
hcfmusp.relation.referenceDownie PF, 1999, CLIN SCI, V97, P255, DOI 10.1042/CS19990084
hcfmusp.relation.referenceFox PR, 2011, J VET INTERN MED, V25, P1010, DOI 10.1111/j.1939-1676.2011.00776.x
hcfmusp.relation.referenceHildebrandt P, 2010, EUR HEART J, V31, P1881, DOI 10.1093/eurheartj/ehq163
hcfmusp.relation.referenceHo CY, 2010, CIRCULATION, V122, P2430, DOI 10.1161/CIRCULATIONAHA.110.978924
hcfmusp.relation.referenceHo CY, 2006, CIRCULATION, V113, pE396, DOI 10.1161/CIRCULATIONAHA.105.579268
hcfmusp.relation.referenceHo CY, 2009, CIRC-CARDIOVASC GENE, V2, P314, DOI 10.1161/CIRCGENETICS.109.862128
hcfmusp.relation.referenceHo CY, 2002, CIRCULATION, V105, P2992, DOI 10.1161/01.CIR.0000019070.70491.6D
hcfmusp.relation.referenceHo CY, 2010, CIRCULATION, V122, P2440
hcfmusp.relation.referenceKaski JP, 2008, HEART, V94, P1307, DOI 10.1136/hrt.2007.126748
hcfmusp.relation.referenceKonno T, 2010, CURR OPIN CARDIOL, V20, P205
hcfmusp.relation.referencePagourelias ED, 2010, INT J CLIN PRACT, V64, P511, DOI 10.1111/j.1742-1241.2009.02184.x
hcfmusp.relation.referencePieroni M, 2007, J CARD FAIL, V13, P380, DOI 10.1016/j.cardfail.2007.01.011
hcfmusp.relation.referenceRakowski H, 1996, J Am Soc Echocardiogr, V9, P736, DOI 10.1016/S0894-7317(96)90076-0
hcfmusp.relation.referenceRedfield MM, 2002, J AM COLL CARDIOL, V40, P976, DOI 10.1016/S0735-1097(02)02059-4
hcfmusp.relation.referenceRodrigues SL, 2008, ARQ BRAS CARDIOL, V90, P46, DOI 10.1590/S0066-782X2008000100008
hcfmusp.relation.referenceROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5
hcfmusp.relation.referenceSAVAGE DD, 1978, CIRCULATION, V58, P402
hcfmusp.relation.referenceSOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1
hcfmusp.relation.referenceTschope C, 2005, EUR HEART J, V26, P2277, DOI 10.1093/eurheartj/ehi406
hcfmusp.relation.referenceYamada H, 2002, J AM SOC ECHOCARDIOG, V15, P1238, DOI 10.1067/mje.2002.12877
hcfmusp.scopus.lastupdate2024-10-12
hcfmusp.sjr23826
relation.isAuthorOfPublication955a013c-ecfc-44c1-94f2-972929ebdcfd
relation.isAuthorOfPublication9fc8d70f-9a22-4326-ba13-db0346392674
relation.isAuthorOfPublication6d8b1a9f-d8c3-4054-b5a6-a7482f032c6f
relation.isAuthorOfPublication1422690b-e719-46f2-a9f1-c15f1cf1eba1
relation.isAuthorOfPublication8fcc68cf-3928-4c9f-ae71-75a55a4cbd33
relation.isAuthorOfPublication9d67a2f7-e589-4fbc-87b0-189fa7dbe111
relation.isAuthorOfPublication48cc5b07-b2f8-4c74-b17b-142ed8fe4174
relation.isAuthorOfPublicationa970d450-bcd4-4662-94d6-ad1c6d043b3c
relation.isAuthorOfPublication415ce7ca-65c1-4699-b6f4-19dae8b03849
relation.isAuthorOfPublicationed3e630e-476e-42c6-bfc6-3c89a5f4eb67
relation.isAuthorOfPublication.latestForDiscovery955a013c-ecfc-44c1-94f2-972929ebdcfd
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_FERNANDES_Plasma_Pro_B_Type_Natriuretic_Peptide_Testing_as_2012.PDF
Tamanho:
141.28 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)